文献速递脊柱关节炎

艾克司单抗对放射学阳性中轴型脊柱关节炎患者MRI骶髂关节结构病变的影响:一项52周随机安慰剂对照试验(含阳性参照臂)的事后分析

The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm.
PubMed 文献 · Lancet Rheumatol · 2025-02-18

本研究为COAST-V试验的事后分析,纳入未使用过生物制剂DMARD的放射学阳性中轴型脊柱关节炎患者,比较艾克司单抗(每2周或每4周80mg)与阿达木单抗及安慰剂对MRI骶髂关节结构病变的影响。第16周时,艾克司单抗每2周组的侵蚀评分较安慰剂显著降低(最小二乘均值-0.91 vs 0.10;p<0.0001),每4周组为-0.57(p=0.0086);艾克司单抗每2周组回填评分较安慰剂显著增加(0.52 vs 0.04;p=0.0042)。第52周时,两种剂量下侵蚀和回填均有进一步变化,以连续艾克司单抗每2周组变化最大。

要点

  • 第16周艾克司单抗每2周组侵蚀评分最小二乘均值-0.91,安慰剂组0.10(p<0.0001)。
  • 第16周艾克司单抗每4周组侵蚀评分最小二乘均值-0.57(p=0.0086)。
  • 第52周连续艾克司单抗每2周组平均侵蚀-1.50(SD 2.70),平均回填0.76(SD 2.09)。

核心结论

  • 第16周观察到侵蚀减少和回填增加,第52周接受艾克司单抗的患者侵蚀进一步减少、回填进一步增加。
  • 艾克司单抗与阿达木单抗一样可改变结构病变,这与放射学阳性中轴型脊柱关节炎患者的快速组织反应一致。
  • 然而,对骶髂关节或脊柱强直发生的影响需要进一步分析。

研究设计与样本

  • COAST-V为3期、多中心、随机、双盲、安慰剂对照试验,设阳性参照臂,为期52周,在12个国家84个中心开展。
  • 纳入年龄≥18岁、未使用过生物制剂DMARD、有活动性放射学阳性中轴型脊柱关节炎、放射学证据显示骶髂关节炎且对非甾体抗炎药反应不足或不耐受的成人患者。
  • 患者按1:1:1:1随机分配至艾克司单抗80mg每2周、艾克司单抗80mg每4周、阿达木单抗40mg每2周或安慰剂。
  • 第16周时,安慰剂组或阿达木单抗组患者再次按1:1随机分配至艾克司单抗每2周或每4周。
  • 报告的是基线、第16周和第52周均有MRI的患者的分析结果。

主要发现

  • 2016年6月20日至2017年8月22日,COAST-V研究共纳入341例患者;基线及第16周有MRI扫描者325例(95%),第52周有MRI扫描者301例(88%)。
  • 325例患者中264例(81%)为男性,61例(19%)为女性,平均年龄41.5岁(SD 11.6)。
  • 第16周,艾克司单抗每2周组侵蚀评分较安慰剂显著降低(最小二乘均值-0.91[SE 0.19] vs 0.10[0.18];p<0.0001),艾克司单抗每4周组为-0.57(SE 0.19;p=0.0086);阿达木单抗效应相似。
  • 第16周,艾克司单抗每2周组回填评分较安慰剂显著增加(0.52[0.12] vs 0.04[0.12];p=0.0042)。
  • 第52周,两种艾克司单抗剂量下侵蚀和回填均有进一步变化,以连续艾克司单抗每2周组变化最大(平均侵蚀-1.50[SD 2.70],平均回填0.76[SD 2.09]);从阿达木单抗在第16周转换至艾克司单抗的患者也观察到侵蚀减少。

关键数值与推荐

  • MRI采用加拿大脊柱关节炎研究联盟骶髂关节结构评分评估侵蚀、回填、脂肪病变和强直。
  • 采用ANCOVA在观察病例中比较治疗效应,校正基线值、骨髓水肿和分层因素。
  • 按性别、HLA-B27和基线骨髓水肿进行亚组分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 对骶髂关节或脊柱强直发生的影响需要进一步分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of biological disease-modifying antirheumatic drugs (DMARDs) on sacroiliac joint lesions over 52 weeks in biological DMARD-naive patients with radiographic axial spondyloarthritis is unknown. This post-hoc analysis evaluated the effect of ixekizumab and adalimumab versus placebo on structural lesions in sacroiliac joints assessed by MRI in patients naive to biological DMARDs with radiographic axial spondyloarthritis from the COAST-V study. METHODS: COAST-V was a phase 3, multicentre, randomised, double-blind, placebo-controlled trial with an active reference arm done over 52 weeks at 84 sites in 12 countries. Eligible patients were adults (aged ≥18 years) naive to biological DMARDs with active radiographic axial spondyloarthritis, radiographic evidence of sacroiliitis, and an inadequate response or intolerance to non-steroidal anti-inflammatory drugs. Patients were randomly assigned (1:1:1:1) to 80 mg ixekizumab every 2 weeks (Q2W) or every 4 weeks (Q4W), 40 mg adalimumab Q2W, or placebo. At week 16, patients receiving placebo or adalimumab were randomly assigned (1:1) again to ixekizumab Q2W or ixekizumab Q4W. Post-hoc analyses of patients with MRI available at baseline, 16 weeks, and 52 weeks are reported. MRIs were scored using the Spondyloarthritis Research Consortium of Canada sacroiliac joint structural scores for erosion, backfill, fat lesions, and ankylosis. ANCOVA was used for treatment comparisons in observed cases adjusting for baseline values, bone marrow oedema, and stratification factors. Subgroup analyses by sex, HLA-B27, and baseline bone marrow oedema were done. FINDINGS: Between June 20, 2016, and Aug 22, 2017, 341 patients were enrolled in the COAST-V study. MRI scans were available for 325 (95%) of 341 patients at baseline and week 16, and for 301 (88%) patients at week 52. 264 (81%) of 325 patients were male and 61 (19%) were female, and the mean age was 41·5 years (SD 11·6). At week 16, erosion significantly decreased versus placebo in the ixekizumab Q2W group (least squares mean -0·91 [SE 0·19] vs 0·10 [0·18]; p<0·0001) and the ixekizumab Q4W group (-0·57 [SE 0·19]; p=0·0086]); the effect of adalimumab was similar. Backfill significantly increased from baseline to week 16 in ixekizumab Q2W versus placebo (0·52 [0·12] vs 0·04 [0·12]; p=0·0042). At week 16, decreases in erosion differed significantly between the placebo group and ixekizumab Q2W or Q4W groups, and differences were seen by sex, HLA-B27 status, and baseline bone marrow oedema score. At week 52, at both ixekizumab doses, further changes were observed in erosion and backfill, which were greatest with continuous ixekizumab Q2W (mean erosion -1·50 [SD 2·70], mean backfill 0·76 [SD 2·09]). A decrease in erosion was also noted in patients switching from adalimumab to ixekizumab at week 16. COAST-V was registered with ClinicalTrials.gov (NCT02696785). INTERPRETATION: A decrease in erosion and increase in backfill were observed at week 16 with further reductions in erosion and increases in backfill occurring at week 52 in patients receiving ixekizumab. Ixekizumab, like adalimumab, modifies structural lesions that is consistent with a rapid tissue response in patients with radiographic axial spondyloarthritis. However, the effect on the development of ankylosis in sacroiliac joints or the spine requires further analysis. FUNDING: Eli Lilly.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Maksymowych WP, Lambert RGW, Bolce RJ, et al. The effect of ixekizumab treatment on MRI sacroiliac joint structural lesions in patients with radiographic axial spondyloarthritis: post-hoc analysis of a 52-week, randomised, placebo-controlled trial with an active reference arm. Lancet Rheumatol. 2025. PMID: 39983751. doi:10.1016/S2665-9913(24)00312-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。